Assessment superseded
Metformin RCT for slowing geographic atrophy progression in age-related macular degeneration
This RCT tested whether metformin, an FDA-approved diabetes drug, could slow geographic atrophy progression in non-diabetic patients with age-related macular degeneration. The abstract does not report sample size, baseline characteristics, duration, outcomes, or results.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jun 9, 2023 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Non-diabetic patients with Age-related Macular Degeneration (AMD)
- Primary outcome
- Safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration
- Effect size
- —
- Significance
- Not reported
- Journal
- University of California, San Francisco
- Published
- Jun 9, 2023
Sources
Primary source
- University of California, San Francisco ↗Clinical trial
- Ophthalmology science ↗Peer reviewed
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.